全球抗蛇毒药物市场 – 行业趋势及 2029 年预测

抗蛇毒药物市场分析及规模

预计全球抗蛇毒药物市场在预测期内将出现大幅增长。根据世界卫生组织的说法，单价抗蛇毒仅限于一种毒蛇或几种密切相关的毒蛇，这些毒蛇的毒液在临床上显示出与抗蛇毒血清有效的交叉中和作用。大约 70% 的蛇咬伤发生在毒蛇咬伤负担较重的州，一半发生在雨季和低海拔地区。印度的蛇咬伤负担很重，这增加了对其治疗药物的需求。

Data Bridge Market Research 分析了 2022-2029 年全球抗蛇毒药物市场的增长率。在上述预测期内，全球抗蛇毒药物市场的预期复合年增长率约为 4.50%。2021 年市场价值为 9.5 亿美元，到 2029 年将增长至 13.5 亿美元。除了市场价值、增长率、细分市场、地理覆盖范围、市场参与者和市场情景等市场洞察外，Data Bridge Market Research 团队策划的市场报告还包括深入的专家分析、患者流行病学、渠道分析、定价分析和监管框架。

抗蛇毒药物市场范围和细分

Market Definition

Antivenom drugs are used to treat venomous bites and stings, usually preferable in high-toxicity cases. Antivenin, venom antiserum, and antivenom immunoglobulin are the different other names of antivenom drugs. These medications can potentially reverse the effects of snake bites, and generally, an adequate therapeutic dose is injected. Additionally, these medications also help in kidney dialysis, artificial respiration, prosthesis as well as rehabilitation services.

Global Antivenom Drugs Market Dynamics

Drivers

• Increasing Drug Approvals

Approvals and launches of novel drugs in the leading regions are anticipated to be a major factor driving antivenom drugs market growth during the forecast period. For instance, in October 2018, Silanes Laboratories received U.S. FDA approval for Anavip, an antivenom against the bite of snakes of the Crotalus family, including the rattlesnake. In 2017, Rare Disease Therapeutics, Inc., partner of Silanes Laboratories, launched Anavip in the U.S. market. Thus, all these factors boost the growth of the market.

• Higher Initiatives by Government and Private Organizations

To satisfy to the demand for antivenom drugs, several market players are opting for many initiatives to strengthen their market presence. For instance, in September 2021, a partnership was made between Papua New Guinea (PNG) and Australia to donate antivenoms and help save the lives of people bitten or stung by venomous snakes and marine creatures. It has been extended for a further two years, 2021-2023. This will provide the availability of antivenomous drugs across the countries, thus driving the market.

Opportunities

• Rising Incidence of Snake Bites

According to the update by World Health Organization in May 2021, nearly 5.4 million snake bites occur each year, leading to up to 2.7 million envenomings (poisoning from snake bites) and around 81,000 to 138,000 deaths because of snake bites. Furthermore, it often leads to about three times as many amputations and other permanent disabilities. As per a research article "Trends in snakebite deaths in India from 2000 to 2019 in a nationally representative mortality study," published in July 2020, India witnessed approximately 1.2 million deaths due to snakebites between 2001-2019. Thus, these increasing cases demand higher antivenom drugs and are boosting the market's growth.

• Increasing Focus on Extension of Shelf Life

The major players in the market are focusing on increasing shelf life and extending the expiry date of their products. For instance, in September 2018, BTG plc. announced that the U.S. FDA has approved updating the shelf life of CroFab Crotalidae Polyvalent Immune Fab (Ovine) up to 60 months. In addition, in 2018, Pfizer, Inc. worked with the U.S. FDA to extend the expiration date of Antivenin's Lot No. L67530 for an additional 12 months. Thus, all these efforts are having an impact on the growth of the market.

Restraints/Challenges

• Lack of skilled professionals

The lack of qualified personnel in developing and underdeveloped economies who cannot treat the patients with appropriate treatments could curb the growth of the global antivenom drugs market over a forecast period.

• High Costs

The huge expenditure required for setting up these techniques hampers the market growth. Several market players make huge investments in installing new and advanced machines to faster the process, and in return, the cost is increased.

This global antivenom drugs market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global antivenom drugs market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

COVID-19 Impact on Global Antivenom Drugs Market

A major increase in the number of deaths recorded because of snake bites during the COVID-19 pandemic in a few areas. This is creating an extensive demand for antivenoms. More than 350 snake bites were stated in Texas in 2020, which was an increase of 40% over the value registered in 2019, as per the June 2020 article titled, "Texas snake bites increasing during COVID-19 pandemic". Additionally, there was a pause in R&D activities related to antivenom due to temporary outages, labor shortages, freight challenges, and a high risk of COVID-19 contamination. This has left a negative impact on the market. Although, with the ease of COVID-19-led restrictions, production activities are projected to resume at the pre-pandemic level. Thus, COVID-19 had a major impact on the market.

Recent Development

• In July 2022, the foundation for Antivenom Research and Development Centre (AVRDC) was conducted at the Institute of Bioinformatics and Applied Biotechnology (IBAB), Bengaluru Helix Biotech Park, Electronics City to increase the production activities for antivenom.
• In April 2022, the Complementary Agreement to the Technical Cooperation Agreement between Brazil and the Government of the Republic of the Union of Myanmar for the implementation of the project "Improving methodologies and techniques for the production of antivenom serum in Myanmar - phase II: antivenom quality" was signed. The aim of the project is to increase the quality and performance of the antivenom serum produced in that Asian country.

Global Antivenom Drugs Market

The global antivenom drugs market is segmented on the basis of type, treatment, animal, mode of action, end-user and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Type

• Monovalent
• Polyvalent

Treatment

• Vaccines
• Hyper Immune

Animal

• Snakes
• Spiders
• Scorpions
• Others

Mode of Action

• Cytotoxic
• Neurotoxic
• Haemotoxic
• Cardiotoxic
• Myotoxic
• Others

End User

• Hospital/Clinical Laboratories
• Physician Offices
• Reference Laboratories
• Others

Distribution Channel

• Direct Tender
• Retail Sales
• Other

Antivenom Drugs Market Regional Analysis/Insights

The global antivenom drugs market is analysed and market size insights and trends are provided by type, treatment, animal, mode of action, end-user and distribution channel as referenced above.

The major countries covered in the global antivenom drugs market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

North America accounts for the largest market share due to the involvement of major drug suppliers, the region's high spending on research and development, and healthcare and qualified professionals.

Asia-Pacific is projected to score the highest market growth rate due to increased research and innovations in the antivenom drugs market. 

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Global Antivenom Drugs Market Share Analysis

全球抗蛇毒药物市场竞争格局按竞争对手提供详细信息。详细信息包括公司概况、公司财务状况、收入、市场潜力、研发投资、新市场计划、全球影响力、生产基地和设施、生产能力、公司优势和劣势、产品发布、产品宽度和广度、应用主导地位。以上提供的数据点仅与公司对全球抗蛇毒药物市场的关注有关。

全球抗蛇毒药物市场的主要参与者包括：

• Bioclone 研究所（墨西哥）
• 辉瑞公司 (美国)
• F. Hoffmann-La Roche Ltd（瑞士）
• 默克集团（德国）
• 罕见疾病治疗公司（美国）
• VINS Bioproducts Ltd（印度）
• BTG International Inc（英国）
• Incepta Pharma（孟加拉国）
• 印度血清和疫苗有限公司 (BSV) (印度)
• 汉密尔顿公司（美国）
• B. Braun SE（德国）
• 康德乐 (美国)
• BD（美国）
• 波士顿科学公司 (美国)
• Alomone Labs（以色列）
• 惠氏有限责任公司（美国）

SKU-55609